Lumida
/BYSI
⌘K
BYSI

BYSI

BYSI
$1.29USD↑+0.78%+0.01 today

MARKET CAP

53.0M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1
$2

The case for & against

Bull & Bear analysis

Bearish

BeyondSpring Inc. (NASDAQ: BYSI) is an emerging player in the biopharmaceutical sector, primarily focusing on innovative oncology solutions. The company is dedicated to developing its lead asset, Penabulin, which targets chemotherapy-induced neutropenia (CIN), a significant complication in cancer treatment. BeyondSpring's strategic partnerships, notably within the Chinese market, and its robust pipeline position it well to capitalize on unmet medical needs in cancer care, particularly in the area of supportive therapies for oncology patients.

Bull says

  • ↑Phase 3 Penabulin trial shows significant survival and neutropenia improvements.
  • ↑Chi Ray partnership in China could deliver up to $171 M in milestone revenue.
  • ↑$72.4 M cash balance supports planned R&D and operations through 2022.
  • ↑NMPA engagement and planned NDA filing in China by year-end drive approval momentum.
  • ↑Addressable CIN market >650,000 US patients annually suggests large revenue opportunity.
  • ↑High oil-price sensitivity and solid quality/sustainability scores point to undervaluation.

Bear says

  • ↓2021 net loss of $64.2 M and Q4 loss of $9.5 M underscore cash burn concerns.
  • ↓Cash runway pressured by R&D spend; may require costly capital raises.
  • ↓FDA intends a second Phase 3 CIN study, pushing US approval beyond 2022.
  • ↓Established GCSF therapies from Amgen, Pfizer, Lilly limit market penetration.
  • ↓Short interest ~1.2 reflects investor skepticism about execution.
  • ↓Weak profitability and earnings yield factors, plus high leverage risk, weigh on valuation.

Earnings Call · Q4 2020 · Mgmt. Guidance

Updated 06-22-2026bullish

Transcript signals

Bull points

  • As of December 31, 2020, we had cash and cash equivalents of $109.5 million on hand, which the company believes is sufficient to support its ongoing clinical programs over the next year, including its immuno-oncology pipeline and to prepare for a potential launch of Plenabulin in 2022.
  • We are thrilled to be turning our attention to the market and the opportunity to tell the story of unmet medical need in the CIN space.
  • Each year, more than 650,000 patients receive chemo. With the recent NCCN guideline change recommending that high and intermediate risk patients receive prophylaxis for CIN, the addressable population has more than doubled to over 70% of the entire chemotherapy patient population.

Bear points

  • Net loss attributable to Beyond Spring Inc. in the fourth quarter of 2020 was $17.6 million compared to $14.1 million for the same period last year.
  • Net loss attributable to Beyond Spring, Inc. was $61.0 million for the year ended December 31, 2020, compared to $38.1 million for the year ended December 31, 2019.
  • The question of timing is a really interesting one. Launching a product late in the year when you get into the holidays is always a dicey proposition. If you look at Coherence as an example, they got approval in September and waited to launch into January. I think that's probably a wise decision because going into the holidays is never a good thing, and the 10 or 12 launches I've done, you never really want to be launching late in the fourth quarter.
Read full transcript analysis ›